Skip to content
Ropivacaine
Naropin (ropivacaine) is a small molecule pharmaceutical. Ropivacaine was first approved as Naropin on 1996-09-24. It is used to treat postoperative pain in the USA. It is known to target sodium channel protein type 5 subunit alpha.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Naropin (generic drugs available since 2014-07-17)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ropivacaine hydrochloride
Tradename
Company
Number
Date
Products
NAROPINFresenius KabiN-020533 RX1996-09-24
11 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
naropinNew Drug Application2022-12-29
ropivacaine hydrochlorideANDA2023-03-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postoperative pain—D010149G89.18
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Ropivacaine Hydrochloride, Naropin, Fresenius Kabi Usa
78578022026-11-28DP
78287872025-10-18DP
81629152024-05-23DP
81188022023-05-18DP
ATC Codes
N: Nervous system drugs
— N01: Anesthetics
— N01B: Local anesthetics
— N01BB: Amide local anesthetics
— N01BB09: Ropivacaine
HCPCS
Code
Description
J2795
Injection, ropivacaine hydrochloride, 1 mg
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VomitingD014839HP_0002013R11.1313——7
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Germ cell and embryonal neoplasmsD009373—1———1
Postoperative nausea and vomitingD020250EFO_0004888—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameROPIVACAINE
INNropivacaine
Description
(S)-ropivacaine is a piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond. It has a role as a local anaesthetic. It is a piperidinecarboxamide and a ropivacaine.
Classification
Small molecule
Drug classlocal anesthetics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Identifiers
PDB—
CAS-ID84057-95-4
RxCUI35780
ChEMBL IDCHEMBL1077896
ChEBI ID8890
PubChem CID175805
DrugBankDB00296
UNII ID7IO5LYA57N (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SCN5A
SCN5A
Organism
Homo sapiens
Gene name
SCN5A
Gene synonyms
NCBI Gene ID
6331
Protein name
sodium channel protein type 5 subunit alpha
Protein synonyms
cardiac tetrodotoxin-insensitive voltage-dependent sodium channel alpha subunit, hH1, Sodium channel protein cardiac muscle subunit alpha, Sodium channel protein type V subunit alpha, sodium channel, voltage-gated, type V, alpha subunit, Voltage-gated sodium channel subunit alpha Nav1.5
Uniprot ID
Q14524
Mouse ortholog
Scn5a (20271)
sodium channel protein type 5 subunit alpha (Q9JJV9)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 9,811 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
889 adverse events reported
View more details